These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 37125931)

  • 1. Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system.
    Bakri SJ; Bektas M; Sharp D; Luo R; Sarda SP; Khan S
    J Manag Care Spec Pharm; 2023 May; 29(5-a Suppl):S2-S11. PubMed ID: 37125931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 3. The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration.
    Fleckenstein M; Mitchell P; Freund KB; Sadda S; Holz FG; Brittain C; Henry EC; Ferrara D
    Ophthalmology; 2018 Mar; 125(3):369-390. PubMed ID: 29110945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
    Heier JS; Lad EM; Holz FG; Rosenfeld PJ; Guymer RH; Boyer D; Grossi F; Baumal CR; Korobelnik JF; Slakter JS; Waheed NK; Metlapally R; Pearce I; Steinle N; Francone AA; Hu A; Lally DR; Deschatelets P; Francois C; Bliss C; Staurenghi G; Monés J; Singh RP; Ribeiro R; Wykoff CC;
    Lancet; 2023 Oct; 402(10411):1434-1448. PubMed ID: 37865470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration.
    Schütze C; Wedl M; Baumann B; Pircher M; Hitzenberger CK; Schmidt-Erfurth U
    Am J Ophthalmol; 2015 Jun; 159(6):1100-1114.e1. PubMed ID: 25769245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outer retinal corrugations in age-related macular degeneration.
    Ooto S; Vongkulsiri S; Sato T; Suzuki M; Curcio CA; Spaide RF
    JAMA Ophthalmol; 2014 Jul; 132(7):806-13. PubMed ID: 24801396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central geographic atrophy vs. neovascular age-related macular degeneration: differences in longitudinal vision-related quality of life.
    Ahluwalia A; Shen LL; Del Priore LV
    Graefes Arch Clin Exp Ophthalmol; 2021 Feb; 259(2):307-316. PubMed ID: 32813108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Cho HJ; Park SM; Kim J; Nah SK; Lee J; Lee DW; Kim JW
    Acta Ophthalmol; 2021 Jun; 99(4):e540-e546. PubMed ID: 32996674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient acceptability of intravitreal complement inhibitors in geographic atrophy (GA): protocol for a UK-based cross-sectional study.
    Dinah C; Enoch J; Ghulakhszian A; Sekhon M; Crabb DP; Taylor DJ
    BMJ Open; 2024 Jan; 14(1):e075713. PubMed ID: 38238063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
    Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
    Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
    Liisborg C
    Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
    Wykoff CC; Rosenfeld PJ; Waheed NK; Singh RP; Ronca N; Slakter JS; Staurenghi G; Monés J; Baumal CR; Saroj N; Metlapally R; Ribeiro R
    Ophthalmology; 2021 Sep; 128(9):1325-1336. PubMed ID: 33711380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruch's Membrane and the Choroid in Age-Related Macular Degeneration.
    Edwards M; Lutty GA
    Adv Exp Med Biol; 2021; 1256():89-119. PubMed ID: 33847999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical Coherence Tomography Features Preceding the Onset of Advanced Age-Related Macular Degeneration.
    Ferrara D; Silver RE; Louzada RN; Novais EA; Collins GK; Seddon JM
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3519-3529. PubMed ID: 28715590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complement system: a novel therapeutic target for age-related macular degeneration.
    Shughoury A; Sevgi DD; Ciulla TA
    Expert Opin Pharmacother; 2023; 24(17):1887-1899. PubMed ID: 37691588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
    Wykoff CC; Clark WL; Nielsen JS; Brill JV; Greene LS; Heggen CL
    J Manag Care Spec Pharm; 2018 Feb; 24(2-a Suppl):S3-S15. PubMed ID: 29383980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation studies of ranibizumab for neovascular age-related macular degeneration.
    Bloch SB
    Acta Ophthalmol; 2013 Nov; 91 Thesis7():1-22. PubMed ID: 24206851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unravelling the therapeutic potential of IL-33 for atrophic AMD.
    Clare AJ; Liu J; Copland DA; Theodoropoulou S; Dick AD
    Eye (Lond); 2022 Feb; 36(2):266-272. PubMed ID: 34531552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study.
    Liao DS; Metlapally R; Joshi P
    Immunotherapy; 2022 Sep; 14(13):995-1006. PubMed ID: 35860926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.